| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 4.29B | — |
| Operating expense | — | — |
| Net income | 1.30B | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, RGO.F returned +47.0% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +8.3% |
| 1 year | +47.0% |
| 5 years | +469.3% |
| 10 years | +469.3% |
| All-time high | €1,068.50 (Aug 2024) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in RGO.F would be worth today ›Yes. Regeneron Pharmaceuticals, Inc. paid 4 dividends over the past 12 months. The most recent was €0.81 per share on Aug 18, 2026. The dividend yield is 0.46%.
Regeneron Pharmaceuticals, Inc. is part of the Healthcare sector.
Regeneron Pharmaceuticals, Inc. has a market cap of 74.05B EUR, based on the latest quote.
Regeneron Pharmaceuticals, Inc. is expected to report earnings around Oct 28, 2026. That date is an estimate and has not been confirmed by the company.
